CD19 and lymphoma: To counteract the immunomodulatory effect of CD47 on B cells, Hawkes et al designed a CD19xCD47 BsAb TG-1801 that blocks CD47 on CD19+ cells thus releasing macrophage anti-lymphoma activity.